Background/Aims: The use of adsorption cartridges for hemoperfusion (HP) is rapidly evolving. For these devices, the potential induced cytotoxicity is an important issue. The aim of this study was to investigate potential in vitro cytotoxic effects of different sorbent cartridges, HA130, HA230, HA330, HA380 (Jafron, China), on U937 monocytes.Methods: Monocytes were exposed to the sorbent material in static and dynamic manners. In static test, cell medium samples were collected after 24 h of incubation in the cartridges. In dynamic test, HP modality has been carried out and samples at 30, 60, 90, and 120 min were collected. Results: Compared to control samples, there was no evidence of increased necrosis or apoptosis in monocytes exposed to the cartridges both in the static and dynamic tests. Conclusion: Our in vitro testing suggests that HA cartridges carry an optimal level of biocompatibility and their use in HP is not associated with adverse reactions or signs of cytotoxicity.

1.
Ronco C, Bellomo R: Acute renal failure and multiple organ dysfunction in the ICU: from renal replacement therapy (RRT) to multiple organ support therapy (MOST). Int J Artif Organs 2002; 25: 733–747.
2.
Ricci Z, Ronco C, Bachetoni A, D’Amico G, Rossi S, Alessandri E, Rocco M, Pietropaoli P: Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care 2006; 10:R67.
3.
Ronco C: Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance. Crit Care 2005; 9: 141–142.
4.
Terragni PP, Birocco A, Faggiano C, Ranieri VM: Extracorporeal CO2 removal. Contrib Nephrol 2010; 165: 185–196.
5.
Costanzo MR, Ronco C: Extracorporeal fluid removal in heart failure patients. Contrib Nephrol 2010; 165: 236–243.
6.
Panagiotou A, Gaiao S, Cruz DN: Extracorporeal therapies in sepsis. J Intens Care Med 2013; 28: 281–295.
7.
Neri M, Villa G, Garzotto F, Bagshaw S, Bellomo R, Cerda J, Ferrari F, Guggia S, Joannidis M, Kellum J, Kim JC, Mehta RL, Ricci Z, Trevisani A, Marafon S, Clark WR, Vincent JL, Ronco C: Nomenclature for ­renal replacement therapy in acute kidney injury: basic principles. Crit Care 2016; 20: 318.
8.
Botella J, Ghezzi PM, Sanz-Moreno C: Adsorption in hemodialysis. Kidney Int Suppl 2000; 76:S60–S65.
9.
Grandi F, Bolasco P, Palladino G, Sereni L, Caiazzo M, Atti M, Ghezzi PM: Adsorption in Extracorporeal Blood Purification: How to Enhance Solutes Removal Beyond Diffusion and Convection; in Suzuki H (ed): Hemodialysis. InTech, 2013.
10.
Gurland HJ, Davison AM, Bonomini V, Falkenhagen D, Hansens S, Kishimoto T, Lysaght MJ, Moran J, Valek A: Definitions and terminology in biocompatibility. Nephrol Dial Transplant 1994; 9(suppl 2): 4–10.
11.
Ash SR, Sullivan TA, Carr DJ: Sorbent suspensions vs. sorbent columns for extracorporeal detoxification in hepatic failure. Ther Apher Dial 2006; 10: 145–153.
12.
Hughes RD, Williams R: Use of sorbent columns and haemofiltration in fulminant hepatic failure. Blood Purif 1993; 11: 163–169.
13.
Hetz H, Berger R, Recknagel P, Steltzer H: Septic shock secondary to beta-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy. Int J Artif Organs 2014; 37: 422–426.
14.
Baumann A, Buchwald D, Annecke T, Hellmich M, Zahn PK, Hohn A: RECCAS – removal of cytokines during cardiac surgery: study protocol for a randomised controlled trial. Trials 2016; 17: 137.
15.
Schadler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, Marx G, Putensen C, Spies C, Jorres A, Quintel M, Engel C, Kellum JA, Kuhlmann MK: The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS One 2017; 12:e0187015.
16.
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C: Early use of polymyxin b hemoperfusion in abdominal septic shock: the euphas randomized controlled trial. JAMA 2009; 301: 2445–2452.
17.
Cutuli SL, Artigas A, Fumagalli R, Monti G, Ranieri VM, Ronco C, Antonelli M: Polymyxin-b hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care 2016; 6: 77.
18.
Ala-Kokko TI, Laurila J, Koskenkari J: A new endotoxin adsorber in septic shock: observational case series. Blood Purif 2011; 32: 303–309.
19.
Winchester JF: Hemoperfusion; in Maher JF (ed): Replacement of Renal Function by Dialysis. Kluwer Academic Publishers 1989, pp 439–459.
20.
Song M, Winchester J, Albright RL, Capponi VJ, Choquette MD, Kellum JA: Cytokine removal with a novel adsorbent polymer. Blood Purif 2004; 22: 428–434.
21.
Linden K, Scaravilli V, Kreyer SF, Belenkiy SM, Stewart IJ, Chung KK, Cancio LC, Batchinsky AI: Evaluation of the cytosorbTM hemoadsorptive column in a pig model of severe smoke and burn injury. Shock 2015; 44: 487–495.
22.
Morris C, Gray L, Giovannelli M: Early report: the use of cytosorbTM haemabsorption column as an adjunct in managing severe sepsis: initial experiences, review and recommendations. J Intensive Care Soc 2015; 16: 257–264.
23.
Nakaji S, Hayashi N: Bilirubin adsorption column medisorba BL-300. Ther Apher Dial 2003; 7: 98–103.
24.
ISO: 10993–5 Biological Evaluation of Medical Devices – Part 5: Tests for in vitro Cytotoxicity, 2009.
25.
Neri M, Virzi GM, Brocca A, Garzotto F, Kim JC, Ramponi F, de Cal M, Lorenzin A, Brendolan A, Nalesso F, Zanella M, Ronco C: In vitro cytotoxicity of bisphenol a in monocytes cell line. Blood Purif 2015; 40: 180–186.
26.
Faouzi MA, Dine T, Gressier B, Kambia K, Luyckx M, Pagniez D, Brunet C, Cazin M, Belabed A, Cazin JC: Exposure of hemodialysis patients to di-2-ethylhexyl phthalate. Int J Pharmaceut 1999; 180: 113–121.
27.
Rueda-Romero C, Hernandez-Perez G, ­Ramos-Godinez P, Vazquez-Lopez I, Quintana-Belmares RO, Huerta-Garcia E, Stepien E, Lopez-Marure R, Montiel-Davalos A, Alfaro-Moreno E: Titanium dioxide nanoparticles induce the expression of early and late receptors for adhesion molecules on monocytes. Part Fibre Toxicol 2016; 13: 36.
28.
Nakamura T, Kharbanda S, Spriggs D, Kufe D: Effects of dexamethasone on induction of monocytic differentiation in human u-937 cells by dimethylsulfoxide. J Cell Physiol 1990; 142: 261–267.
29.
Sundstrom C, Nilsson K: Establishment and characterization of a human histiocytic lymphoma cell line (u-937). Int J Cancer 1976; 17: 565–577.
30.
Clark WR, Ferrari F, La Manna G, Ronco C: Extracorporeal sorbent technologies: basic concepts and clinical application. Contrib Nephrol 2017; 190: 43–57.
31.
Li WH, Yin YM, Chen H, Wang XD, Yun H, Li H, Luo J, Wang JW: Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus. Medicine 2017; 96:e6160.
32.
Chen SJ, Jiang GR, Shan JP, Lu W, Huang HD, Ji G, Wu P, Wu GF, Wang W, Zhu C, Bian F: Combination of maintenance hemodialysis with hemoperfusion: a safe and effective model of artificial kidney. Int J Artif Organs 2011; 34: 339–347.
33.
Huang Z, Wang SR, Su W, Liu JY: Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial 2010; 14: 596–602.
34.
Huang Z, Wang SR, Yang ZL, Liu JY: Effect on extrapulmonary sepsis-induced acute lung injury by hemoperfusion with neutral microporous resin column. Ther Apher Dial 2013; 17: 454–461.
35.
Hu XB, Gao HB, Liao ME, He MR: [The use of ha330-ii microporous resin plasma adsorption in the treatment of chronic severe hepatitis]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2007; 19: 760–761.
36.
Sun S, He L, Bai M, Liu H, Li Y, Li L, Yu Y, Shou M, Jing R, Zhao L, Huang C, Wang H: High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study. Ann Saudi Med 2015; 35: 352–358.
37.
Shi Y, Bai Y, Zou Y, Cai B, Liu F, Fu P, Wang L: The value of plasma paraquat ­concentration in predicting therapeutic effects of haemoperfusion in patients with acute paraquat poisoning. PLoS One 2012; 7:e40911.
38.
Hoenich NA: Biocompatibility of sorbent systems. Contrib Nephrol 2002: 165–169.
39.
Kokubo K, Kurihara Y, Kobayashi K, Tsukao H, Kobayashi H: Evaluation of the biocompatibility of dialysis membranes. Blood Purif 2015; 40: 293–297.
40.
Tice RR, Austin CP, Kavlock RJ, Bucher JR: Improving the human hazard characterization of chemicals: a tox21 update. Environ Health Perspect 2013; 121: 756–765.
41.
Raine A, Cordonnier D, Ritz E: Effect of hematodialysis plus hemoperfusion on insulin resistance and nutritional status of patients with end-stage diabetic nephropathy. J Translat Med 2015; 3: 180–184.
42.
Liu L, Ding G: Effects of different blood purification methods on serum cytokine levels and prognosis in patients with acute severe organophosphorus pesticide poisoning. Ther Apher Dialysis 2015; 19: 185–190.
43.
Bellomo R, Ronco C: Blood purification in the intensive care unit: evolving concepts. World J Surgery 2001; 25: 677–683.
44.
Haase M, Kellum JA, Ronco C: Subclinical AKI – an emerging syndrome with important consequences. Nat Rev Nephrol 2012; 8: 735–739.
45.
Bellomo R, Ronco C, Metha R: Nomenclature for continuous renal replacement therapies. Off J Natl Kidney Found 1996; 28:S2–S7.
46.
Ronco C, Brendolan A, Dan M, Piccinni P, Bellomo R, De Nitti C, Inguaggiato P, Tetta C: Adsorption in sepsis. Kidney Int Suppl 2000; 76:S148–S155.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.